Challenges with 177Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical Practice

被引：0
|
作者：
Jadvar, Hossein [1 ,2 ]
Iravani, Amir [3 ]
Bodei, Lisa [4 ]
Calais, Jeremie [5 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Div Nucl Med, Los Angeles, CA 90007 USA
[2] Univ Southern Calif, Mol Imaging Ctr, Keck Sch Med, Dept Radiol, Los Angeles, CA 90007 USA
[3] Univ Washington, Dept Radiol, Div Nucl Med, Seattle, WA USA
[4] Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY USA
[5] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷 / 12期
关键词：
RESISTANT PROSTATE-CANCER; PROGRESSION-FREE SURVIVAL; PSMA PET/CT; 177LU-PSMA-617; MULTICENTER; SAFETY;
D O I：
10.2967/jnumed.124.268023
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：1851 / 1854
页数：4
相关论文
共 50 条
  • [21] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [22] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
  • [23] 177Lu-PSMA-617 therapy in Chemotherapy Naive patients: A single center experience
    Kulkarni, Raksha
    Abdelrahman, Ahmed
    Novello, Matteo
    Cengiz, Turgut Bora
    Akinlusi, Rahman
    Bander, Ilda
    Patel, Vaibhav
    Wise, David
    Ghesani, Munir
    Ghesani, Nasrin
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [24] 177Lu-PSMA-617 Therapy in a Patient on Haemodialysis with End Stage Renal Failure
    MacFarlane, L.
    Eifer, M.
    Saghebi, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S248 - S248
  • [25] Formulation of clinical-scale 177Lu-PSMA-617: From laboratory to clinics
    Das, Tapas
    Guleria, Mohini
    Banerjee, Sharmila
    NUCLEAR MEDICINE AND BIOLOGY, 2016, 43 (12) : 835 - 836
  • [26] First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
    van Kalmthout, Ludwike
    Braat, Arthur
    Lam, Marnix
    van Leeuwaarde, Rachel
    Krijger, Gerard
    Ververs, Tessa
    Mehra, Niven
    Bins, Adriaan
    Hunting, Jarmo
    de Keizer, Bart
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 446 - 451
  • [27] Prognostic value of baseline imaging parameters prior to therapy with 177Lu-PSMA-617
    Ferdinandus, Justin
    Thang, Sue Ping
    Violet, John
    Hicks, Rodney
    Sandhu, Shahneen
    Hofman, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [28] Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Kiess, Ana
    Lukens, J. Nicholas
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2025, 15 (01) : 14 - 18
  • [29] Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)
    Pathmanandavel, Sarennya
    Crumbaker, Megan
    Ho, Bao
    Yam, Andrew O.
    Wilson, Peter
    Niman, Remy
    Ayers, Maria
    Sharma, Shikha
    Hickey, Adam
    Eu, Peter
    Stockler, Martin
    Martin, Andrew J.
    Joshua, Anthony M.
    Nguyen, Andrew
    Emmett, Louise
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (02) : 221 - 226
  • [30] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, Christina Nguyen
    Happel, Christian
    Davis, Karen
    Groener, Daniel
    Mader, Nicolai
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
12345